10 November 2020

Cardiovascular diseases, such as stroke or myocardial infarction, are caused by the narrowing and closure of arteries by plaques, as a result of a process called atherosclerosis. Important risk factors for atherosclerosis are high cholesterol, high blood pressure, diabetes and obesity.

Our innate immune system plays an important role in the development of these plaques via chronic inflammation, and previous research has shown that drugs which inhibit inflammation can indeed reduce the occurrence of cardiovascular diseases.

Zooming in on the immune system in atherosclerosis

Macrophages are important immune cells from the innate immune system, and the most common type of immune cells in atherosclerotic plaques. They are derived from another cell type - monocytes - that is present in the blood. In patients with cardiovascular disease, these monocytes are more active, producing more inflammatory molecules than in healthy individuals. It is not yet clear how these monocytes are activated in patients with cardiovascular disease.

In this study, published in eLife, a small group of 13 patients with coronary heart disease, due to severe coronary atherosclerosis, was compared to a group of 13 patients without atherosclerosis. In these study participants a bone marrow puncture was performed so that the researchers could isolate and study the residing stem cells. These stem cells are the precursor cells of all blood cells, including the monocytes. The researchers showed that in patients with atherosclerosis, these precursor cells were programmed differently, so that they produced more activated monocytes.

What does this mean for our knowledge of the immune system and future treatments?

This study adds an extra dimension to the role of the immune system in the development of cardiovascular diseases by showing that activation of this system takes place at the level of precursor cells in the bone marrow.

Niels Riksen, theme Vascular damage and last author of the article: 'This finding could explain how risk factors for cardiovascular disease, such as high cholesterol or obesity, can have a long-term effect on the immune system. In addition, this knowledge is relevant and important for the development of new drugs targeting the immune system for the treatment or prevention of cardiovascular diseases'.

read more

Related news items


Veni grants for RIMLS researchers

16 December 2021

NWO has awarded 89 promising young scientists Veni funding of up to 280,000 euros. Three of them are from Radboud Institute of Molecular Life Sciences (RIMLS). They can develop their own research ideas over a period of three years.

read more

Technology saves lives! 1.9 million euros from the Heart Foundation for developing smart watches

17 November 2021

Niels van Royen is proud to be part of this consortium, initiated by Judith Bonnes, to develop a wrist band for early detection of cardiac arrest. Together with Erasmus, Reinier de Graaf and Corsano Health.

read more

Tiny blood vessels, big problems Radboudumc receives grant for international collaboration

3 November 2021

The Radboudumc, together with the University of Cambridge, receives a grant of €1.8M from three collaborating cardiac foundations for international research into the small blood vessels in the brain. This study will be led by Neurologist Frank-Erik de Leeuw and internist Niels Riksen.

read more

RIMLS awards call for nominations

19 October 2021

RIMLS awards several prizes to stimulate and honor our (young) researchers. Upcoming awards are Supervisor of the Year, Best Master Thesis, Best Publication, Best Image and more. Send your nominations now before 24 November 2021.

read more

Turbo Grants for four medical-technical research projects

19 October 2021

Four TURBO grants were recently awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between the University of Twente (TechMed Centre) and the Radboudumc.

read more

COVID-19 associated coagulopathy - lessons after 1 year

17 May 2021

Jenneke Leentjens, Saskia Middeldorp, and colleagues, published a review on the current knowledge of COVID-19 associated coagulopathy and the role of antithrombotic therapies in the Lancet Haematology.

read more